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Abstract
A conformational study of ketoprofen was carried out by both density functional theory (DFT) calculations and Raman spectroscopy. Nine
different geometries were found to correspond to energy minimum conformations but only one of them was experimentally detected in the
condensed phase spectra.
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dThose rotations which interconvert the five most stable conformers were studied and the intramolecular interactions governing the corresponding
onformational preferences were assessed.
A thorough vibrational analysis was performed, leading to the assignment of both the solid and liquid spectra. Evidence for formation of
ntermolecular hydrogen bonds between carboxylic groups of adjacent ketoprofen molecules, leading to dimeric entities, was obtained.
2005 Elsevier B.V. All rights reserved.
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. Introduction
The development process of solid pharmaceutical dosage
orms should imply a previous thorough characterisation of the
rugs, as most probably its solid-state structure has a relevant
nfluence on both its stability and bioavailability (Byrn et al.,
994,1995). In fact, the conformational preferences of the drug
ay determine the chemical and/or physical mechanisms (i.e.
ntermolecular interactions), which control its release into the
ody from a particular delivery system.
Several methods can be applied in order to get structural infor-
ation on a certain species as well as to understand interactions
etween this active agent and distinct compounds (excipients
nd/or carriers). Among them, Raman spectroscopy has been
uccessfully used for the characterisation and quantification
f various solid-state forms of drugs (Niemczyk et al., 1998;
arques et al., 2002; Szostak and Mazurek, 2002), including
olymorphs (Deeley et al., 1991; Tudor et al., 1993; Forster et
l., 1999), amorphous materials (Taylor and Zografi, 1997,1998)
∗
and salts (Findlay and Bugay, 1998). Also, found in the litera-
ture are studies on the characterisation of drugs within different
supports (Taylor and Langkilde, 2000), as polymeric matrices
(Davies et al., 1990a,b; Watts et al., 1991; Breienbach et al.,
1999; Kazarian and Martirosyan, 2002) or cyclodextrins (Choi
et al., 2001).
Ketoprofen (Fig. 1A), chemically [2-(3-benzoylphenyl) pro-
pionic acid], a weak acid (pKa = 4.6), poorly water-soluble type
drug (water solubility value ≈ 0.13 mg/ml−1 at 25 ◦C), is one
type of “profen” class of non-steroid anti-inflammatory drug
(NSAID). This drug contains a chiral center at the -carbon
to the carboxyl function and therefore exists as R(−) and S(+)
enantiomeric forms. According to Mullangi et al. (2003), its anti-
inflammatory activity, as determined by in vivo cyclo-oxygenase
inhibition, resides almost exclusively with the S-enantiomer.
Ketoprofen has been shown to act as an analgesic, antipyretic and
anti-inflammatory effects, and used for the treatment of rheuma-
toid arthritis, osteoarthritis and ankylosis spondylitis (Cathcart
et al., 1973; Fossgreen, 1976; Fossgreen et al., 1976; Julou et al.,
1976), and also for non-rheumatoid diseases (Avouac and Teule,
1988). Its mechanism of action is mainly based on inhibitory
effects on prostaglandin and leukotrien synthesis (Vargaftig andCorresponding author. Tel.: +351 239854462; fax: +351 239826541.
E-mail address: labc@ci.uc.pt (L.A.E.B. de Carvalho). Dao, 1971), as well as antibradykinin effects and lysosomal
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Fig. 1. (A–E) Schematic representation of the five most stable conformers of ketoprofen molecule.
membrane stabilising activity (Stiegler et al., 1995). Ketopro-
fen’s half-life in blood plasma was found to be between 2 and 3 h
(Martindale, 1996). This short half-life, coupled to the low single
administration dosage necessary, renders ketoprofen a very good
candidate for the formulation of controlled release dosage forms
(Caruso et al., 1982; Houghton et al., 1984a,b; Marcolongo et
al., 1984; Morley et al., 1984; Giunchedi et al., 1991; Le Liboux
et al., 1994; Habib and Meuse, 1995; Khan et al., 1996; Parejo
et al., 1998; Vergote et al., 2001; Roda et al., 2002; Palmieri et
al., 2002; Vueba et al., 2004). However, the exact nature of the
mechanisms underlying drug controlled release processes is still
unknown.
Raman spectroscopy, long established as a non-invasive
method particularly adequate to study both intra- and inter-
molecular interactions, allows a comparative investigation of
drug performance, in the solid state, either when mixed with the
required excipients in the formulation of the matrix tablets or in
other pharmaceutical dosage forms (Breienbach et al., 1999;
Scranton et al., 2000; Vankeirsbilck et al., 2002; Vergote et
al., 2002, 2004; De Beer et al., 2004). Moreover, Raman spec-
troscopy can be applied without any particular sample prepara-
tion, thus avoiding mechanical influences, which may alter the
physicochemical properties of the formulation. In order to per-
form this kind of study, the conformational preferences of the
ketoprofen molecule must be previously determined and assign-
ment of its Raman features should be carried out. This could be
a
t
ents, has lately become more and more important, as extended-
release (either constant or pulsed) dosage forms of the drug
may often be beneficial. Thus, the knowledge of intermolecular
interactions between ketoprofen and these polymers/excipients,
which regulates the drug release processes within the body, is
of the utmost importance. This may be accomplished through
Raman spectroscopy, once the conformational behaviour of the
pure drug in the solid state is known. The present study aims
at achieving this goal, which will hopefully allow to carry
out future studies on ketoprofen tablets (composed of distinct
drug/polymer/excipient mixtures).
In this work, a conformational study on ketoprofen was
undertaken by Raman spectroscopy combined to DFT calcu-
lations. The FTIR spectrum of ketoprofen in a KBr disk was
also analysed, in order to explore the well known comple-
mentary between these two optical vibrational spectroscopy
techniques.
2. Materials and methods
2.1. Chemicals
Ketoprofen, batch no. 043K0684, was purchased from
Sigma–Aldrich Chemie, Germany.
2.2. Raman spectroscopy
mchieved with the help of MO calculations.
The possibility of preparing ketoprofen hydrophilic matrix
ablets using cellulosic polymers and different required excipi-
The Raman spectra were obtained on a triple monochro-
ator Jobin-Yvon T64000 Raman system (focal distance
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0.640 m, aperture f/7.5) equipped with holographic gratings of
1800 grooves mm−1. The premonochromator stage was used in
the subtractive mode. The detection system was liquid nitrogen
cooled non-intensified 578 × 385 pixel (1/2 in.) charge coupled
device (CCD) chip. A Coherent (model Innova 300-05) Ar+
laser was used as light source, the output of which at 514.5 nm
was adjusted to provide 35 mW at the sample position. A 90◦
geometry, between the incident radiation and the collecting sys-
tem, was employed. The entrance slit was set to 200m and the
slit between the premonochromator and the spectrograph was
opened to 12 mm. An integration time of 3 s and 10–15 scans
were used in all experiments.
Samples were sealed in Kimax glass capillary tubes of
0.8 mm inner diameter. Under the above-mentioned conditions,
the error in wavenumbers was estimated to be within 1 cm−1.
A home-made Harney–Miller type assembly (Miller and
Harney, 1970) was used for recording the spectrum of liquid
ketoprofen which required a temperature of ca. 370 K.
2.3. FTIR spectroscopy
Infrared spectra of ketoprofen in KBr disks (ca. 5%, w/w)
were recorded at room temperature on a Nicolet Model 740
FTIR spectrometer, in the range 400–4000 cm−1, using a globar
source, a Ge/KBr beamsplitter, a DTGS detector. The spectra
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were always less than 3 × 10−4 Hartree bohr−1 or Hartree rad−1.
In order to study the barriers to internal rotation, the geometries
were optimised for different fixed internal rotation angles.
The quantitative potential energy deconvolution was based on
least-squares fitted Fourier type functions of a torsional angle,
V = V0 +
3∑
n=1
1
2
Vn[1 − cos(nτ)] +
∑
n=1,2,4
V ′n sin(nτ)
where τ is the HC8C1C6 dihedral angle (Fig. 1) and V are func-
tional values that correspond to potential energy differences
relative to a reference value (V0 is the energy corresponding
to a HC8C1C6 angle of 0◦).
3. Results and discussion
3.1. Conformational analysis
Ketoprofen molecule can adopt different conformations,
mainly by varying the dihedral angles around the C1 C8,
C8 C10 and C10 O12 bonds (Fig. 1). Conformational energy
minima not separated by more than 7 kJ mol−1 from the most
stable conformer are shown in Fig. 1. Table 1 comprises the con-
formational energy differences, dipole moments and rotational
constants of all the conformers found. The s-trans arrangement
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C E
A 0.0
B 2.1
C 6.1
D 6.4
E 5.5
A 18.8
B 22.2
C 34.3
E 31.9ere collected in 32 scans to a 16,384 data points file (resolu-
ion ca. 2 cm−1) and subject to a Happ–Genzel apodisation. The
rrors in wavenumbers were estimated to less than 1 cm−1.
.4. DFT calculations
The molecular orbital calculations were carried out with the
AUSSIAN 98W program (Frisch et al., 1998), within the
ensity functional theory (DFT) approach, using the B3LYP
ethod, which includes a mixture of Hartree–Fock (HF) and
FT exchange terms. The gradient-corrected correlation func-
ional was used (Lee et al., 1988; Miehlich et al., 1989), parame-
erised after Becke (1988,1993), along with the double-zeta split
alence basis set 6-31G* (Hariharan and Pople, 1973).
Molecular geometries were fully optimised by the Berny
lgorithm, using redundant internal coordinates (Peng et al.,
996): the bond lengths to within ca. 0.1 pm and the bond angles
o within ca. 0.1◦. The final root-mean-square (rms) gradients
able 1
onformational energies, dipole moments (µ) and rotational constants calculat
onformation HC8C O; HC8C1C6 (◦)
−157.9; −169.1
−150.1; 7.4
15.0; −173.7
20.2; −44.1
17.4; 2.1
′ −109.5; −176.0
′ −100.7; 1.6
′ 25.1; −147.9
′ 28.4; 5.3
a 1 D = 1/3 × 10−2 C m.O C O H angle ca. 180◦, not shown in Fig. 1), whenever
resent, was found to be significantly less stable (by about
8 kJ mol−1) than their s-cis counterpart (O C O H angle ca.
◦
, Fig. 1), and is referred to along the text using primes (e.g. A′
nd A, respectively, for conformer A) (Fig. 2).
The results now obtained were to be expected in view of
he conclusions from previous conformational studies on pro-
ionic and 2-methylpropionic acids (Siam et al., 1984; Batista
e Carvalho et al., 1990; Teixeira-Dias et al., 1991). In fact, in
hese kinds of molecules, the preferred conformations around the
 C bond are the ones displaying -substituents with either
yn or skew orientations relative to the C O bond (CCC O
quals 0◦ or ±120◦, respectively).
Table 2 comprises the B3LYP/6-31G* optimised geometry
alculated for the most stable conformation (results for the
ther conformers and parameters involving hydrogen atoms are
vailable from the authors upon request), as well as the X-ray
xperimental geometry determined by Briard and Rossi (1990).
the ketoprofen conformers
(kJ mol−1) µa (D) A; B; C (GHz)
0 2.12 1.095; 0.157; 0.149
5 4.09 0.818; 0.178; 0.170
2 4.41 1.096; 0.157; 0.148
2 2.21 0.909; 0.169; 0.161
1 2.20 0.832; 0.177; 0.169
5.79 1.113; 0.158; 0.150
6.54 0.835; 0.175; 0.169
5.96 1.126; 0.154; 0.148
4.29 0.821; 0.178; 0.169
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Fig. 2. Schematic representation of the conformational energies calculated for
ketoprofen conformers.
The quantum mechanical results now obtained are in quite good
agreement with the experimental ones.
It is worthwhile to note that the two aromatic rings of the
ketoprofen molecule are not coplanar (Fig. 1). In fact, the planes
containing the C3 C4 and C1′ C6′ bonds, for instance, were
found, for all conformers, to define a dihedral angle of ca. 50◦ in
good accordance with X-ray experimental value of 53◦ (Briard
and Rossi, 1990).
Rotational isomerism in this kind of compounds – contain-
ing both aromatic rings, carbonyl and carboxylic groups – is
influenced by different factors, from steric, dipolar, mesomeric
and hyperconjugative effects, to hydrogen bonding interactions.
Moreover, the relative importance of intramolecular versus inter-
molecular interactions (e.g. dimer formation) has often proved,
in several systems, to be determinant of their conformational
preferences, either as pure compounds or in solution.
Once the s-cis conformers are significantly more stable than
s-trans ones (Fig. 2), the rotational isomerism around the C1 C8
bond for a HOC O dihedral ca. 0◦ (s-cis) was studied. Two par-
ticular cases were considered: HC8C O ca. −155◦ or 15◦, corre-
sponding to energy minima around the C8 C10 internal rotation.
The C1 C8 rotation converts conformers A to B (Fig. 3a), as
well as C to D and E (Fig. 4a), for HC8C O ca. −155◦ and 15◦,
respectively.
The energy difference between B and the more stable A
conformer is 2.15 kJ mol−1, the corresponding internal rotation
b
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d
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Table 2
Calculated (B3LYP/6-31G*) and experimental (X-ray; Briard and Rossi, 1990)
geometrical parameters for the most stable conformer (A) of ketoprofen
Coordinatea Experimental Calculated
Bond length (pm)
C2 C1 136.7 139.4
C6 C1 138.5 140.4
C8 C1 153.2 152.8
C3 C2 139.3 140.4
C4 C3 139.5 140.2
C7 C3 148.8 150.2
C5 C4 138.1 139.5
C6 C5 139.2 139.4
O13 C7 121.8 122.6
C1′ C7 148.7 150.1
C9 C8 151.8 154.0
C10 C8 151.5 152.3
O11 C10 124.8 121.3
O12 C10 125.4 135.3
C2′ C1′ 138.8 140.4
C6′ C1′ 139.3 140.4
C3′ C2′ 137.8 139.1
C4′ C3′ 136.7 139.8
C5′ C4′ 137.4 139.6
C6′ C5′ 138.2 139.5
Bond angle (◦)
C6 C1 C2 118.6 118.8
C8 C1 C2 119.8 120.2
C8 C1 C6 121.5 121.1
C3 C2 C1 121.4 121.3
C4 C3 C2 119.8 119.1
C7 C3 C2 118.6 117.5
C7 C3 C4 121.5 123.2
C5 C4 C3 119.1 119.9
C6 C5 C4 120.1 120.4
C5 C6 C1 121.1 120.4
O13 C7 C3 119.6 119.6
C1′ C7 C3 121.4 120.7
C1′ C7 O13 119.0 119.7
C9 C8 C1 112.4 111.9
C10 C8 C1 110.3 109.7
C10 C8 C9 110.0 110.2
O11 C10 C8 119.1 125.4
O12 C10 C8 117.6 120.0
O12 C10 O11 123.3 122.6
C2′ C1′ C7 118.9 117.7
C6′ C1′ C7 122.5 123.1
C6′ C1′ C2′ 118.5 119.1
C3′ C2′ C1′ 120.4 120.5
C4′ C3′ C2′ 120.6 120.0
C5′ C4′ C3′ 119.9 119.9
C6′ C5′ C4′ 120.2 120.1
C5′ C6′ C1′ 120.3 120.3
Torsional angle (◦)
C2 C1 C8 C10 116.0 129.0
C6 C1 C8 C10 −67.6 −52.4
C1 C8 C10 O11 72.2 85.1
C1 C8 C10 O12 −107.3 −93.6
C2 C3 C7 C1′ 159.3 154.5
C4 C3 C7 C1′ −25.3 −29.5
C3 C7 C1′ C2′ 147.5 153.8
C3 C7 C1′ C6′ −36.0 −30.1
a See Fig. 1 for atom numbering.arrier (A → B) being 12.3 kJ mol−1 (Fig. 3a). Considering the
alues of the Fourier components of the potential energy depen-
ence on this rotation (Fig. 3b and c), it can be concluded that the
argely dominant contribution is represented by a cosine term in
2 (11.0 kJ mol−1), thus favouring those conformations where
teric hindrance is minimised, mainly by displaying the most
oluminous groups – both methyl and carboxyl – away from the
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Fig. 3. Optimised (B3LYP/6-31G*) conformational energy profile for the inter-
nal rotation around the C1 C8 bond of ketoprofen for HC8C O ca. −155◦ (a)
and its Fourier deconvolution (b and c).
closest phenyl, which corresponds to the geometries where each
of the former are positioned above and below the ring (dihedral
HC8C1C6 being either 0◦ or 180◦).
The V1 term (−1.41 kJ mol−1) favours those conformations
having a HC8C1C6 dihedral close to 180◦, which reflects the
stronger attractive interaction between the C10 O11 carbonyl
group and the H17 atom in conformer A – giving rise to a six-
membered intramolecular ring – as compared to the interaction
between this carbonyl group and the H14 hydrogen in geometry
B. Moreover, the greater stabilisation of the A conformer rel-
ative to B may be explained in terms of the balance between
the following factors (Fig. 5): the stabilising interaction due the
presence, in both geometries, of a bifurcated H23 ↔ O13 ↔ H14
acceptor; the bifurcated O13 ↔ H14 ↔ O11 donor interaction
which occurs in B; and the O11 ↔ H17 hydrogen bond found
in A. In fact, the sharing of H14 between two adjacent H-type
Fig. 4. Optimised (B3LYP/6-31G*) conformational energy profile for the inter-
nal rotation around the C1 C8 bond of ketoprofen for HC8C O ca. 15◦ (a) and
its Fourier deconvolution (b and c).
bonds is, in this particular molecule, an energetically unfavour-
ing factor, as it is responsible for a significant weakening of the
H14 ↔ O11 interaction (dH14O11 equal to 281 pm, in B, versus
dH17O11 equal to 261 pm, in A).
The V3 term (−0.60 kJ mol−1), in turn, reflects the steric hin-
drance between the H17 atom and any one of the C8 substituents
(either H, COOH or CH3). Thus, energy maxima occur for a
Fig. 5. Schematic representation of the intramolecular interactions found in the
A and B ketoprofen conformers.
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HC8C1C6 dihedral equal to 0◦, 120◦ and −120◦, while minima
are detected for 60◦, 180◦ and −60◦ (Fig. 3b).
As to the sine terms, the most important one was found to be
V ′4 [−1.22 kJ mol−1, Fig. 3c]. This contribution can be explained
in the light of electrostatic factors occurring within the molecule.
In fact, it displays maxima for those conformations where repul-
sive interactions arise, between the positively charged H19 and
H20 methyl hydrogens and the aromatic H14 or H17 atoms. On
the other hand, V ′4 presents energy minima whenever the methyl
group is positioned such as to minimise this kind of destabilising
interactions: either above or below the ring plane, in a perpen-
dicular position; or, alternatively, with C9 and H21 in the ring
plane, and both H19 and H20 positioned symmetrically relative
to H14 or H17 atoms.
On the other hand, the three conformers displaying a
HC8C O dihedral of ca. 15◦ are about 3–6 kJ mol−1 higher
than A and B (Table 1; Fig. 2). The following potential energy
differences were calculated: −0.30 kJ mol−1 for E(C–D),
0.91 kJ mol−1 for E(D–E) and 0.61 kJ mol−1 for E(C–E),
while the barrier of internal rotation converting conformer C into
D/E is 8.3 kJ mol−1 (Fig. 4a). Interesting enough is the detection
of an unexpected minimum – species D – for HC8C1C6 equal to
−44.1◦ (Fig. 4), which is confirmed beyond doubt by the absence
of negative calculated vibrational frequencies for this geometry.
This low energy conformer arises from a H17 ↔ O11 hydrogen
bond type interaction (d equal to 281 pm). However, the
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Fig. 6. Raman spectra (100–1750 and 2500–3300 cm−1) of ketoprofen in the:
solid (a) and liquid (b) phases.
respectively; d = 264.0 pm) is stronger than the H17 ↔ O12
one present in the C conformer (Mulliken charges: 0.152 and
−0.564, respectively; d = 251.5 pm). Comparing repulsive rela-
tions, in turn, the H17 ↔ H18 destabilising interaction in the E
conformer (Mulliken charges: 0.138 and 0.165, respectively;
d = 228.0 pm) is weaker than the H14 ↔ H18 one present in the
C conformer (Mulliken charges: 0.165 and 0.177, respectively;
d = 230.0 pm).
3.2. Vibrational analysis
Fig. 6 comprises the Raman spectra for both the solid and liq-
uid ketoprofen, in the 100–1750 and 2500–3300 cm−1 regions.
Fig. 7 contains the FTIR spectrum for solid ketoprofen, in the
400–1800 and 2300–3500 cm−1 intervals. Experimental Raman
and FTIR wavenumbers are presented in Table 3, along with the
DFT calculated values for the two most stable conformers, A and
B (Fig. 1). The agreement between the experimental and calcu-
lated wavenumbers, after scaling according to Scott and Radom
(1996) in order to correct for the unharmonicity of the normal
modes of vibration, was found to be rather good. In fact, as
the calculated energy difference between B and the most stable
A conformer is only 2.15 kJ mol−1, either of these conformers
may have significative populations at room temperature. How-
ever, the calculated values for the low frequency region (below
6 −1
a
A
f
F
aH17O11
otation barrier corresponding to the D to E interconvertion pro-
ess is surprisingly small – ca. 0.3 kJ mol−1 – corresponding,
n fact, to a free rotation process for temperatures above 36 K.
hus, despite its low conformational energy, the population of
onformer D should not be significant, once the energy of the
rst vibrational level (calculated value: 0.23 kJ mol−1) and this
otational barrier are of the same order of magnitude. Actually,
he torsion associated to the HC8C1C6 dihedral, probably dis-
laying a rather large amplitude, is proposed to be the process
esponsible for the D ↔ E interconvertion.
Moreover, conformer D′ is not detected, once the stabilisation
ue to the occurrence of a H17 ↔ O11 intermolecular interaction
previously described) is overruled by the geometrical rearrange-
ent associated to the presence of the hydroxyl H22 atom near
he CH3 group (which, in turn, is in close proximity to the H14
ydrogen; Fig. 1).
When comparing the graphic representations and their
ourier components, for both rotational processes studied
Figs. 3 and 4), it can be concluded that there is an obvious
imilarity between them. Thus, independently of their mag-
itude, the V2 [7.65 kJ mol−1, Fig. 4b], V3 [−0.79 kJ mol−1,
ig. 4b] and V ′4 [−1.20 kJ mol−1, Fig. 4c] terms could be inter-
reted in the light of the same type of interactions as the ones
escribed above. On the other hand, the V1 term [1.58 kJ mol−1,
ig. 4b] exhibits an inverse behaviour relative to HC8C1C6
ihedral angle: conformations with this dihedral close to 0◦
re the preferred ones. The greater stabilisation of the E con-
ormer relative to C could be almost completely explained by
he examination of the magnitude of electrostatic interactions
resent in both. Actually, in the E conformer the H14 ↔ O12
tabilising interaction (Mulliken charges: 0.174 and −0.562,00 cm ), which is the most conformationally sensitive one,
re remarkably consistent with the sole presence of conformer
, both for liquid and solid ketoprofen.
Table 3 also contains the complete assignment of ketopro-
en observed bands to the normal modes of vibration. It is
ig. 7. FTIR spectrum (400–1800 and 2300–3500 cm−1) of solid ketoprofen in
KBr disk.
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Table 3
Experimental (Raman and FTIR) and DFT MO-calculated harmonic wavenumbers (cm−1) and intensities for ketoprofen
Raman FTIR Calculateda Approximate descriptionsb
Liquid Solid Conformer A Conformer B
110 96 (6; 0) C7  C8 wagging (10b)
124 117 (7; 1) C7  C8 wagging (10b)
138 136 (1; 1) 140 (2; 2) C7 O13 out-of-plane bending
157 148 (4; 2) ′ C7 wagging (10b)
170 184 (1; 0) CH3 C  deformation; C7  C8 bending (10a)
201 (5; 0) ′ C7 wagging (10b); C7  C8 wagging (10b)
223 220 220 (6; 1) C7  C8 bending (10a); ′ C7  deformation
229 (0; 0) 230 (1; 0) CH3 C torsion
236 (3; 1) C7  C8 bending (10a); CH3 C torsion
260 259 253 (1; 2) 254 (0; 4) CH3 C (C O) deformation
294 290 296 (4; 1) 300 (2; 0) CH3 C  deformation; (O13 C7) ′ torsion
310 – – Overtone (2 × 157 cm−1)
317 – – Combination mode (157 + 170 cm−1)
370 369 (1; 1) 357 (2; 1) C7  C8 bending G (15); C C OH deformation
385 385 (1; 7) 384 (1; 8) C7 O13 in-plane bend; , ′ out-of-plane bend (16b)
408 408 421 (2; 0) 419 (2; 0) ′ out-of-plane bending (16a)
432 430 427 432 (3; 7) 436 (1; 4) C C OH deformation
441 441 (1; 0) 446 (1; 5)  out-of-plane bending (16b)
446 453 450 456 (1; 3) 454 (1; 4) ′ out-of-plane bending (16b)
508 518 514 513 (2; 3) 515 (3; 1) C O H bending;  out-of-plane bending (16a)
582 593 588 570 (4; 15) 552 (3; 10) C O H bending
608 608 588 (6; 37) 592 (6; 22)  (16a), ′ (16b) out-of-plane bend; C O H bend
608 (5; 0) 607 (4; 12) ′ in-plane bending (6b)
620 621 614
615 (5; 64) 609 (5; 46) C O H out-of-plane bending
630 (3; 15) 636 (4; 20) C O H out-of-plane bend; , ′ in-plane bend (6a)
647 642 642
642 (4; 73) 634 (3; 90) C O H bending;  (6b), ′ (6a) in-plane bending
677 671 677 (1; 10) 675 (2; 8) , ′ out-of-plane bending (4)
696 691 688 (3; 9) 685 (11; 14)  out-of-plane bend (4); ′ CH out-of-plane bend (11)
706 708 703 692 (9; 22) 689 (4; 21) ′ CH out-of-plane bend (11);  out-of-plane bend (4)
724 718 717 708 (4; 54) 707 (4; 52) , ′ CH out-of-plane bending (11)
750 (1; 12) 745 (1; 14) C O H out-of-plane bending
776 773
773 (3; 11) 770 (2; 4) , ′ CH out-of-plane wagging
787 790 787 792 (4; 12) CH3 rocking
803 (3; 39) CH3 rocking;  CH out-of-plane wagging
∼821 814 811 808 (4; 11)  CH out-of-plane wagging
832 827 837 (6; 3) 836 (5; 3) ′ CH out-of-plane bending (10a)
856 857
∼858 867 866 830 (6; 47) 826 (5; 26) C O H in-plane bending; CH3 rocking
914 918 916 916 (1; 2) 915 (2; 3) ′ (17b),  (17a) CH out-of-plane bending
931 934 929 922 (1; 0) 917 (2; 5)  (17a), ′ (17b) CH out-of-plane bending
959 946 (1; 1) 943 (3; 5) ′ (17a) CH out-of-plane bending
972 970 968 951 (7; 32) 945 (3; 24) CH3 rock;  ring deformation (7b);  CH bend (17b)
987 968 (1; 1) 967 (1; 1) ′ CH out-of-plane bending (5)
996 993 975 (27; 3) 978 (20; 2)  ring deformation (12); CH3 rocking
1003
1005 1003 979 (35; 0) 980 (58; 1) ′ ring deformation (12)
1030 1028 1026 1018 (18; 1) 1019 (14; 1) ′ CH in-plane bending (18a)
1065 1066 1061 1065 (1; 15) 1070 (2; 15) CH3 rocking
1082 1081 1078 1059 (4; 47) 1050 (2; 34) CH3 rock; C CH3 stretching; C O H in-plane bend
1104 1108 1106 1090 (6; 5) 1088 (10; 24)  CH in-plane bending (18a)
1141 1138 1135 1119 (18; 13) 1116 (16; 13)  C ′ symmetric stretch
1163 1160 1158 1149 (7; 1) 1148 (8; 0) ′ CH in-plane bending (9b)
1175 1163 (5; 38) 1162 (4; 21)  (9b), ′ (9a) CH in-plane bending
1182 1180 1182 1167 (6; 14) 1166 (7; 22)  (9b), ′ (9a) CH in-plane bending
1202 1198 1196 1178 (68; 49) 1178 (56; 34) , ′ ring deform (13), C1 ′ C7, C1 C8 stretching
1223 1228 1137 (3; 225) 1136 (4; 210) C O H in-plane bend; C O stretching
1262 1262 1260 1245 (7; 22) 1238 (13; 139)  CH in-plane bending (3); C O H in-plane bending
1286 1281 1285 1252 (21; 301) 1255 (13; 165) , ′ ring deform (13), C1 ′ C7 C3 antisymmetric stretch
M.L. Vueba et al. / International Journal of Pharmaceutics 307 (2006) 56–65 63
Table 3 (Continued )
Raman FTIR Calculateda Approximate descriptionsb
Liquid Solid Conformer A Conformer B
1306 1309 1305 (2; 3) 1310 (2; 14)  CH in-plane bending (3); C8 H bending
1315 (2; 2) 1315 (3; 2) ′ C C stretching (14)
1316 1321 1320
1317 (5; 4) 1318 (3; 12)
1340 ∼1330
1370 1364 (2; 45) 1357 (3; 58) C10 C8 H deformation
1381 1382 1382 1381 (3; 11) 1386 (3; 6) CH3 symmetric deformation
1421 1424 (10; 35) 1424 (6; 17)  C C stretching (19a); C1 C8 H deformation
1440 1434 1444 1435 (4; 17) 1435 (4; 16) ′ C C stretching (19b)
1450 1445 1463 (14; 4) 1462 (16; 4) CH3 antisymmetric deformation
∼1460 1462 1457 1468 (18; 11) 1469 (17; 8) CH3 antisymmetric deformation
∼1485 1484 1481 1472 (4; 4) 1472 (2; 7)  C C stretching (19b); CH3 antisymmetric deform
1491 1491 1480 (5; 1) 1480 (5; 1) ′ C C stretching (19a)
1573 (7; 6) 1573 (6; 6) ′ C C stretching (8b)
∼1579 1576
1574 (34; 9) 1575 (27; 8)  C C stretching (8a)
∼1584 ∼1588 1584 1590 (125; 17) 1590 (117; 21)  C C stretching (8b)
1600 1601 1599 1594 (115; 15) 1594 (117; 16) ′ C C stretching (8a)
1662 1657 1655 1671 (142; 141) 1674 (133; 122) C7 O13 stretching
∼1705 1697 1763 (5; 229) 1770 (5; 225) C10 O11 stretching (H-bonded)
2539 – – Combination mode
2590 2590 ∼2595 – – Combination mode
2618 2625 2626 – – Combination mode
2645 – – Combination mode
2737 2731 2734 – – Combination mode
2884 2881 2879 – – Combination mode
2913 2912 2905 – – Combination mode
2942 2942 2939
2956 ∼2954 2945 (141; 24) 2948 (138; 24) CH3 symmetric stretching
2987 2982 2979 2972 (45; 6) 2961 (67; 11) C8 H18 stretching
3003 3001 2997 3011 (110; 29) 3013 (112; 28) CH3 antisymmetric stretching
∼3030 3030 3026 3030 (31; 13) 3034 (28; 13) CH3 antisymmetric stretching
3058 3054 3063 (51; 0) 3062 (51; 0) ′ C H stretching
3065 ∼3061 3069 (63; 7) 3061 (69; 6)  C H stretching
3069 3073 ∼3069 3073 (142; 13) 3073 (138; 11) ′ C H stretching
∼3088 3083 (133; 35) 3083 (160; 31) ′ C H stretching
3085 (31; 4) 3094 (29; 1) C2 H14 stretching
3097 (172; 11) 3096 (179; 11) ′,  C H stretching
3096
3100 (157; 7) 3100 (152; 7) ′ C H stretching
3151 Overtone/combination mode
3160
3166 Overtone/combination mode
3195 3195 Overtone/combination mode
3295 3535 (183; 52) 3537 (150; 48) OH stretching (H-bonded)
a At the B3LYP/6-31G* level of calculation; wavenumbers above 600 cm−1 scaled by a factor of 0.9614 (Scott and Radom, 1996); in parentheses: Raman scattering
activities in A˚ u−1 and infrared intensities in km mol−1.
b The commonly used Wilson notation for descriptions of benzene derivatives normal vibrations (Wilson, 1934; Varsa´nyi, 1974) is presented inside parentheses.
worthwhile to mention that most of the observed frequencies
can be considered as group frequencies, i.e. highly localised
to a particular group within the ketoprofen molecule. From
these assignments, it may be concluded that the experimental
vibrational spectra confidently reflect the presence of specific
intermolecular interactions. In particular, bands at 1705 and
3295 cm−1, assigned to C10 O11 and O H stretching vibrations,
respectively, display a downward shift relative to the calculated
values for the isolated molecule (Table 3), due to intermolecular
hydrogen bond type interactions. These close-contacts, which
occur through the carboxylic groups of adjacent molecules,
are responsible for the presence of ketoprofen dimeric entities
in condensed phases. These conclusions are corroborated by
the upward shifts detected for the C O H deformation modes
(Table 3).
It should also be mentioned that ketoprofen dimer formation
does not seem to involve a noticeable conformational rearrange-
ment, each monomer retaining its minimum energy geometry.
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4. Conclusions
The MO calculations yield nine different energy minimum
conformations. In general, the two aromatic rings of the ketopro-
fen molecule are not coplanar and the s-trans arrangement of the
carboxylic group, whenever present, is found to be significantly
less stable (by about 18 kJ mol−1) than the s-cis counterpart.
This energy difference rules out the occurrence of a significant
population of s-trans conformers, at room temperature.
Intra- and intermolecular CH···O weak hydrogen bonds have
been extensively studied (Desiraju and Steiner, 1999 and refer-
ences therein) and are often determinant of the conformational
characteristics of the systems, both in the solid and in solution.
In the ketoprofen molecule presently investigated these kind of
interactions are, as discussed above, of the utmost importance.
In fact, they are responsible for the stabilisation of two particular
conformers (A and B) relative to all other calculated minimum
energy geometries (Table 1).
Despite the small energy difference (2.15 kJ mol−1) between
these two most stable conformers, the optical vibrational spec-
troscopy results allow to conclude that only the lowest energy
geometry is present both in the liquid and solid phases of
ketoprofen. Furthermore, evidence of intermolecular hydro-
gen bonds between carboxylic groups of adjacent ketoprofen
molecules, leading to dimers, is also obtained.
The disruption of the dimeric species present in condensed
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